Tapewire

Nasdaq · USD

TSHA

Taysha Gene Therapies, Inc.

Export transactions ↓
Tapewire entity
4549
SEC CIK
0001806310
Parsed reports
120

Last 12 months

Inside the activity.

0 purchase rows · 12 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202501
Dec 202501
Jan 202607
Feb 202601
Mar 202600
Apr 202601
May 202600
Jun 202600
Jul 202601
Aug 202600
Sep 202600
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
July 10, 2026 Filed Jul 10, 2026 22:54 UTC
Nagendran SukumarDirector · President and Head of R&D
SaleCommon Stock 200,000 $6.24 $1,248,000.00
Disclosure

SEC source: 0001665124-26-000013 · form4-07102026_100732.xml · nonDerivative · entry 1

Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 936,410

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.99 to $6.52 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
June 01, 2026 Filed Jun 2, 2026 20:30 UTC GrantStock Option (right to buy) · Derivative 42,671 $0.00 Strike: $5.97 $0.00
Disclosure

SEC source: 0001709418-26-000002 · form4-06022026_040616.xml · derivative · entry 3

Stalfort John A III · CIK 0001709418 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,671

Underlying: Common Stock · 42,671 shares

Expires 2036-06-01

F3 · derivative.exercise_date: The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.

Read SEC document
June 01, 2026 Filed Jun 2, 2026 20:30 UTC GrantCommon Stock 21,335 $0.00 $0.00
Disclosure

SEC source: 0001709418-26-000002 · form4-06022026_040616.xml · nonDerivative · entry 1

Stalfort John A III · CIK 0001709418 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,176,559

F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.

Read SEC document
June 01, 2026 Filed Jun 2, 2026 20:30 UTC GrantStock Option (right to buy) · Derivative 42,671 $0.00 Strike: $5.97 $0.00
Disclosure

SEC source: 0001238120-26-000008 · form4-06022026_040614.xml · derivative · entry 2

Donenberg Phillip B. · CIK 0001238120 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,671

Underlying: Common Stock · 42,671 shares

Expires 2036-06-01

F2 · derivative.exercise_date: The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.

Read SEC document
June 01, 2026 Filed Jun 2, 2026 20:30 UTC GrantCommon Stock 21,335 $0.00 $0.00
Disclosure

SEC source: 0001238120-26-000008 · form4-06022026_040614.xml · nonDerivative · entry 1

Donenberg Phillip B. · CIK 0001238120 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 241,289

F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.

Read SEC document
June 01, 2026 Filed Jun 2, 2026 20:30 UTC GrantStock Option (right to buy) · Derivative 42,671 $0.00 Strike: $5.97 $0.00
Disclosure

SEC source: 0001891712-26-000002 · form4-06022026_040612.xml · derivative · entry 2

Long Alison S · CIK 0001891712 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,671

Underlying: Common Stock · 42,671 shares

Expires 2036-06-01

F2 · derivative.exercise_date: The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.

Read SEC document
June 01, 2026 Filed Jun 2, 2026 20:30 UTC GrantCommon Stock 21,335 $0.00 $0.00
Disclosure

SEC source: 0001891712-26-000002 · form4-06022026_040612.xml · nonDerivative · entry 1

Long Alison S · CIK 0001891712 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 127,178

F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.

Read SEC document
June 01, 2026 Filed Jun 2, 2026 20:30 UTC GrantStock Option (right to buy) · Derivative 42,671 $0.00 Strike: $5.97 $0.00
Disclosure

SEC source: 0001777421-26-000005 · form4-06022026_040610.xml · derivative · entry 2

Sepp-Lorenzino Laura · CIK 0001777421 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,671

Underlying: Common Stock · 42,671 shares

Expires 2036-06-01

F2 · derivative.exercise_date: The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.

Read SEC document
June 01, 2026 Filed Jun 2, 2026 20:30 UTC GrantCommon Stock 21,335 $0.00 $0.00
Disclosure

SEC source: 0001777421-26-000005 · form4-06022026_040610.xml · nonDerivative · entry 1

Sepp-Lorenzino Laura · CIK 0001777421 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 127,178

F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.

Read SEC document
April 10, 2026 Filed Apr 13, 2026 20:33 UTC
Nagendran SukumarDirector · President and Head of R&D
Exercise / conversionEmployee Stock Option (right to buy) · Derivative 19,021 $0.00 Strike: $1.71 $0.00
Disclosure

SEC source: 0001665124-26-000011 · form4-04132026_080454.xml · derivative · entry 3

Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 455,920

Underlying: Common Stock · 19,021 shares

Expires 2034-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

Read SEC document
April 10, 2026 Filed Apr 13, 2026 20:33 UTC
Nagendran SukumarDirector · President and Head of R&D
SaleCommon Stock 200,000 $4.46 $892,000.00
Disclosure

SEC source: 0001665124-26-000011 · form4-04132026_080454.xml · nonDerivative · entry 2

Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,136,410

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.335 to $4.625 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
April 10, 2026 Filed Apr 13, 2026 20:33 UTC
Nagendran SukumarDirector · President and Head of R&D
Exercise / conversionCommon Stock 19,021 $1.71 $32,525.91
Disclosure

SEC source: 0001665124-26-000011 · form4-04132026_080454.xml · nonDerivative · entry 1

Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,336,410

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 04, 2026 Filed Feb 6, 2026 21:30 UTC
Alam KamranCHIEF FINANCIAL OFFICER
SaleCommon Stock 1,655 $4.52 $7,480.60
Disclosure

SEC source: 0001793412-26-000012 · form4-02062026_040223.xml · nonDerivative · entry 1

Alam Kamran · CIK 0001793412 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,442,131

F1 · shares: The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.

Read SEC document
January 26, 2026 Filed Jan 27, 2026 21:05 UTC
Nagendran SukumarDirector · President and Head of R&D
SaleCommon Stock 26,918 $4.61 $124,091.98
Disclosure

SEC source: 0001665124-26-000008 · form4-01272026_040105.xml · nonDerivative · entry 2

Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,317,389

F1 · shares: The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.505 to $4.715 inclusive.

Read SEC document
January 26, 2026 Filed Jan 27, 2026 21:05 UTC
Nolan Sean P.Director · Chief Executive Officer
SaleCommon Stock 41,312 $4.61 $190,448.32
Disclosure

SEC source: 0001569926-26-000008 · form4-01272026_040103.xml · nonDerivative · entry 2

Nolan Sean P. · CIK 0001569926 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,908,257

F1 · shares: The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.505 to $4.715 inclusive.

Read SEC document
January 26, 2026 Filed Jan 27, 2026 21:05 UTC
Alam KamranCHIEF FINANCIAL OFFICER
SaleCommon Stock 23,849 $4.61 $109,943.89
Disclosure

SEC source: 0001793412-26-000008 · form4-01272026_040101.xml · nonDerivative · entry 2

Alam Kamran · CIK 0001793412 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,443,786

F1 · shares: The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.505 to $4.715 inclusive.

Read SEC document
January 23, 2026 Filed Jan 27, 2026 21:05 UTC
Nagendran SukumarDirector · President and Head of R&D
SaleCommon Stock 89,132 $4.75 $423,377.00
Disclosure

SEC source: 0001665124-26-000008 · form4-01272026_040105.xml · nonDerivative · entry 1

Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,344,307

F1 · shares: The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.635 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).

Read SEC document
January 23, 2026 Filed Jan 27, 2026 21:05 UTC
Nolan Sean P.Director · Chief Executive Officer
SaleCommon Stock 136,789 $4.75 $649,747.75
Disclosure

SEC source: 0001569926-26-000008 · form4-01272026_040103.xml · nonDerivative · entry 1

Nolan Sean P. · CIK 0001569926 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,949,569

F1 · shares: The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.635 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).

Read SEC document
January 23, 2026 Filed Jan 27, 2026 21:05 UTC
Alam KamranCHIEF FINANCIAL OFFICER
SaleCommon Stock 78,968 $4.75 $375,098.00
Disclosure

SEC source: 0001793412-26-000008 · form4-01272026_040101.xml · nonDerivative · entry 1

Alam Kamran · CIK 0001793412 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,467,635

F1 · shares: The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.635 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).

Read SEC document
January 12, 2026 Filed Jan 14, 2026 21:45 UTC
Alam KamranCHIEF FINANCIAL OFFICER
GrantEmployee Stock Option (right to buy) · Derivative 231,000 $0.00 Strike: $4.86 $0.00
Disclosure

SEC source: 0001793412-26-000002 · form4-01142026_040105.xml · derivative · entry 2

Alam Kamran · CIK 0001793412 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 231,000

Underlying: Common Stock · 231,000 shares

Expires 2036-01-12

F2 · derivative.exercise_date: 25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

Read SEC document
January 12, 2026 Filed Jan 14, 2026 21:45 UTC
Alam KamranCHIEF FINANCIAL OFFICER
GrantCommon Stock 359,000 $0.00 $0.00
Disclosure

SEC source: 0001793412-26-000002 · form4-01142026_040105.xml · nonDerivative · entry 1

Alam Kamran · CIK 0001793412 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,546,603

F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date.

Read SEC document
January 12, 2026 Filed Jan 14, 2026 21:45 UTC
Nolan Sean P.Director · Chief Executive Officer
GrantEmployee Stock Option (right to buy) · Derivative 648,000 $0.00 Strike: $4.86 $0.00
Disclosure

SEC source: 0001569926-26-000002 · form4-01142026_040103.xml · derivative · entry 3

Nolan Sean P. · CIK 0001569926 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 648,000

Underlying: Common Stock · 648,000 shares

Expires 2036-01-12

F3 · derivative.exercise_date: 25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

Read SEC document
January 12, 2026 Filed Jan 14, 2026 21:45 UTC
Nolan Sean P.Director · Chief Executive Officer
GrantCommon Stock 1,008,000 $0.00 $0.00
Disclosure

SEC source: 0001569926-26-000002 · form4-01142026_040103.xml · nonDerivative · entry 1

Nolan Sean P. · CIK 0001569926 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,086,358

F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date.

Read SEC document
January 12, 2026 Filed Jan 14, 2026 21:45 UTC
Nagendran SukumarDirector · President and Head of R&D
GrantEmployee Stock Option (right to buy) · Derivative 274,000 $0.00 Strike: $4.86 $0.00
Disclosure

SEC source: 0001665124-26-000002 · form4-01142026_040101.xml · derivative · entry 7

Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 274,000

Underlying: Common Stock · 274,000 shares

Expires 2036-01-12

F6 · derivative.exercise_date: 25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

Read SEC document
January 12, 2026 Filed Jan 14, 2026 21:45 UTC
Nagendran SukumarDirector · President and Head of R&D
Exercise / conversionEmployee Stock Option (right to buy) · Derivative 88,676 $0.00 Strike: $1.71 $0.00
Disclosure

SEC source: 0001665124-26-000002 · form4-01142026_040101.xml · derivative · entry 6

Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 474,941

Underlying: Common Stock · 88,676 shares

Expires 2034-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: 25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

Read SEC document
January 12, 2026 Filed Jan 14, 2026 21:45 UTC
Nagendran SukumarDirector · President and Head of R&D
Exercise / conversionEmployee Stock Option (right to buy) · Derivative 111,324 $0.00 Strike: $0.70 $0.00
Disclosure

SEC source: 0001665124-26-000002 · form4-01142026_040101.xml · derivative · entry 5

Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 111,359

Underlying: Common Stock · 111,324 shares

Expires 2033-12-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The shares underlying the option vested or shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date.

Read SEC document
January 12, 2026 Filed Jan 14, 2026 21:45 UTC
Nagendran SukumarDirector · President and Head of R&D
GrantCommon Stock 427,000 $0.00 $0.00
Disclosure

SEC source: 0001665124-26-000002 · form4-01142026_040101.xml · nonDerivative · entry 4

Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,433,439

F3 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date.

Read SEC document
January 12, 2026 Filed Jan 14, 2026 21:45 UTC
Nagendran SukumarDirector · President and Head of R&D
SaleCommon Stock 200,000 $4.71 $942,000.00
Disclosure

SEC source: 0001665124-26-000002 · form4-01142026_040101.xml · nonDerivative · entry 3

Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,006,439

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.565 to $4.92 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 12, 2026 Filed Jan 14, 2026 21:45 UTC
Nagendran SukumarDirector · President and Head of R&D
Exercise / conversionCommon Stock 88,676 $1.71 $151,635.96
Disclosure

SEC source: 0001665124-26-000002 · form4-01142026_040101.xml · nonDerivative · entry 2

Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,206,439

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 12, 2026 Filed Jan 14, 2026 21:45 UTC
Nagendran SukumarDirector · President and Head of R&D
Exercise / conversionCommon Stock 111,324 $0.70 $77,804.34
Disclosure

SEC source: 0001665124-26-000002 · form4-01142026_040101.xml · nonDerivative · entry 1

Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,117,763

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 01, 2025 Filed Dec 2, 2025 01:58 UTC
Nagendran SukumarDirector · President and Head of R&D
Exercise / conversionEmployee Stock Option (right to buy) · Derivative 260,047 $0.00 Strike: $1.71 $0.00
Disclosure

SEC source: 0001665124-25-000003 · form4-12022025_011240.xml · derivative · entry 8

Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 563,617

Underlying: Common Stock · 260,047 shares

Expires 2034-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: 25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

Read SEC document
December 01, 2025 Filed Dec 2, 2025 01:58 UTC
Nagendran SukumarDirector · President and Head of R&D
SaleCommon Stock 260,047 $4.51 $1,172,811.97
Disclosure

SEC source: 0001665124-25-000003 · form4-12022025_011240.xml · nonDerivative · entry 5

Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,006,439

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.42 to $4.63 inclusive.

Read SEC document
December 01, 2025 Filed Dec 2, 2025 01:58 UTC
Nagendran SukumarDirector · President and Head of R&D
Exercise / conversionCommon Stock 260,047 $1.71 $444,680.37
Disclosure

SEC source: 0001665124-25-000003 · form4-12022025_011240.xml · nonDerivative · entry 4

Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,266,486

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 28, 2025 Filed Dec 2, 2025 01:58 UTC
Nagendran SukumarDirector · President and Head of R&D
Exercise / conversionEmployee Stock Option (right to buy) · Derivative 39,953 $0.00 Strike: $1.71 $0.00
Disclosure

SEC source: 0001665124-25-000003 · form4-12022025_011240.xml · derivative · entry 7

Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 823,664

Underlying: Common Stock · 39,953 shares

Expires 2034-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: 25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

Read SEC document
November 28, 2025 Filed Dec 2, 2025 01:58 UTC
Nagendran SukumarDirector · President and Head of R&D
Exercise / conversionEmployee Stock Option (right to buy) · Derivative 70,172 $0.00 Strike: $0.70 $0.00
Disclosure

SEC source: 0001665124-25-000003 · form4-12022025_011240.xml · derivative · entry 6

Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 222,683

Underlying: Common Stock · 70,172 shares

Expires 2033-12-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The shares underlying the option vested or shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date.

Read SEC document
November 28, 2025 Filed Dec 2, 2025 01:58 UTC
Nagendran SukumarDirector · President and Head of R&D
SaleCommon Stock 110,125 $4.75 $523,093.75
Disclosure

SEC source: 0001665124-25-000003 · form4-12022025_011240.xml · nonDerivative · entry 3

Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,006,439

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.7248 to $4.8348 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2).

Read SEC document
November 28, 2025 Filed Dec 2, 2025 01:58 UTC
Nagendran SukumarDirector · President and Head of R&D
Exercise / conversionCommon Stock 39,953 $1.71 $68,319.63
Disclosure

SEC source: 0001665124-25-000003 · form4-12022025_011240.xml · nonDerivative · entry 2

Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,116,564

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 28, 2025 Filed Dec 2, 2025 01:58 UTC
Nagendran SukumarDirector · President and Head of R&D
Exercise / conversionCommon Stock 70,172 $0.70 $49,043.21
Disclosure

SEC source: 0001665124-25-000003 · form4-12022025_011240.xml · nonDerivative · entry 1

Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,076,611

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
September 10, 2025 Filed Sep 12, 2025 20:15 UTC
Nagendran SukumarDirector · President and Head of R&D
Exercise / conversionEmployee Stock Option (right to buy) · Derivative 41,150 $0.00 Strike: $0.70 $0.00
Disclosure

SEC source: 0001415889-25-024369 · form4-09122025_040917.xml · derivative · entry 3

Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 292,855

Underlying: Common Stock · 41,150 shares

Expires 2033-12-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The shares underlying the option vested or shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date.

Read SEC document
September 10, 2025 Filed Sep 12, 2025 20:15 UTC
Nagendran SukumarDirector · President and Head of R&D
SaleCommon Stock 200,000 $3.23 $646,000.00
Disclosure

SEC source: 0001415889-25-024369 · form4-09122025_040917.xml · nonDerivative · entry 2

Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,006,439

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.165 to $3.31 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
September 10, 2025 Filed Sep 12, 2025 20:15 UTC
Nagendran SukumarDirector · President and Head of R&D
Exercise / conversionCommon Stock 41,150 $0.70 $28,759.74
Disclosure

SEC source: 0001415889-25-024369 · form4-09122025_040917.xml · nonDerivative · entry 1

Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,206,439

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 21, 2025 Filed Aug 22, 2025 20:15 UTC
Nagendran SukumarDirector · President and Head of R&D
SaleCommon Stock 57,054 $2.85 $162,603.90
Disclosure

SEC source: 0001415889-25-022750 · form4-08222025_040806.xml · nonDerivative · entry 1

Nagendran Sukumar · CIK 0001665124 · Director · President and Head of R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,165,289

F1 · shares: Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.841 to $2.865 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
August 21, 2025 Filed Aug 22, 2025 20:15 UTC
Alam KamranCHIEF FINANCIAL OFFICER
SaleCommon Stock 54,491 $2.85 $155,299.35
Disclosure

SEC source: 0001415889-25-022749 · form4-08222025_040804.xml · nonDerivative · entry 1

Alam Kamran · CIK 0001793412 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,187,603

F1 · shares: Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.841 to $2.865 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
June 02, 2025 Filed Jun 4, 2025 20:15 UTC GrantStock Option (right to buy) · Derivative 113,246 $0.00 Strike: $2.79 $0.00
Disclosure

SEC source: 0001415889-25-015574 · form4-06042025_040609.xml · derivative · entry 3

Stalfort John A III · CIK 0001709418 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 113,246

Underlying: Common Stock · 113,246 shares

Expires 2035-06-02

F3 · derivative.exercise_date: The shares vest on the earlier of June 2, 2026 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.

Read SEC document
June 02, 2025 Filed Jun 4, 2025 20:15 UTC GrantCommon Stock 56,623 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-015574 · form4-06042025_040609.xml · nonDerivative · entry 1

Stalfort John A III · CIK 0001709418 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,155,224

F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 2, 2026 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.

Read SEC document
June 02, 2025 Filed Jun 4, 2025 20:15 UTC GrantStock Option (right to buy) · Derivative 113,246 $0.00 Strike: $2.79 $0.00
Disclosure

SEC source: 0001415889-25-015573 · form4-06042025_040607.xml · derivative · entry 2

Donenberg Phillip B. · CIK 0001238120 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 113,246

Underlying: Common Stock · 113,246 shares

Expires 2035-06-02

F2 · derivative.exercise_date: The shares vest on the earlier of June 2, 2026 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.

Read SEC document
June 02, 2025 Filed Jun 4, 2025 20:15 UTC GrantCommon Stock 56,623 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-015573 · form4-06042025_040607.xml · nonDerivative · entry 1

Donenberg Phillip B. · CIK 0001238120 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 219,954

F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 2, 2026 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.

Read SEC document
June 02, 2025 Filed Jun 4, 2025 20:15 UTC GrantStock Option (right to buy) · Derivative 113,246 $0.00 Strike: $2.79 $0.00
Disclosure

SEC source: 0001415889-25-015572 · form4-06042025_040604.xml · derivative · entry 2

Long Alison S · CIK 0001891712 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 113,246

Underlying: Common Stock · 113,246 shares

Expires 2035-06-02

F2 · derivative.exercise_date: The shares vest on the earlier of June 2, 2026 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.

Read SEC document
June 02, 2025 Filed Jun 4, 2025 20:15 UTC GrantCommon Stock 56,623 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-015572 · form4-06042025_040604.xml · nonDerivative · entry 1

Long Alison S · CIK 0001891712 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,843

F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 2, 2026 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.

Read SEC document
June 02, 2025 Filed Jun 4, 2025 20:15 UTC GrantStock Option (right to buy) · Derivative 113,246 $0.00 Strike: $2.79 $0.00
Disclosure

SEC source: 0001415889-25-015571 · form4-06042025_040601.xml · derivative · entry 2

Sepp-Lorenzino Laura · CIK 0001777421 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 113,246

Underlying: Common Stock · 113,246 shares

Expires 2035-06-02

F2 · derivative.exercise_date: The shares vest on the earlier of June 2, 2026 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.